NanoLogix Inc (NNLX)

[Omar8]

Here are a few more releases in 2020...




Some interesting stuff happening it seemed in 2020....The Faros seemed positive with that release about partial funding for those 3 million shares ? But nothing seemed to really work out.



"Nov. 24, 2020

Rapid COVID19 Test Patent Granted

Full details of the granted patent, with the complete list of twenty-five granted claims are available in the USPTO Patent Gazette publication

We are pleased to announce the patent for rapid viral testing and diagnosis has been granted and issued by the United States Patent and Trademark Office (USPTO) with a US patent number of 10844442. Information on the published patent can be accessed in the USPTO Official Gazette for Patents and entering the patent number through this link:

http://patentsgazette.uspto.gov/week47/OG/patent.html

There are many extremely vital aspects to this technology. In addition to very accurate and rapid detection of the COVID19 Spike Protein and Virion, another essential capability of the assay is its ability to rapidly detect the presence of the neutalizing antibody to the virus, a quality that can determine both the need for vaccination and the effectiveness and longevity of the neutralizing antibodies. Development work on the technology has indicated potential detection times of twenty minutes or less.

An international patent application under the Patent Cooperation Treaty (PCT) and a Continuation In Part (CIP) were filed this past weekend to provide international patent protection by broadening the geographic and technological scope of the Intellectual Property protection and to add additional aspects to the technology that have been discovered or invented since the original application date.

A formal Press Release will be issued next week after the Thanksgiving Holiday weekend.


Nov. 11, 2020

Rapid COVID19 Test Patent Update

Patent filed May 18 Grant and Issuance will Occur within Two Weeks

We are pleased to announce the patent for rapid viral testing and diagnosis is scheduled for grant and issuance by the United States Patent and Trademark Office (USPTO) in less than two weeks. Information on the patent should be published in the USPTO Official Gazette for Patents on November 24th. Prior to that date both an international patent application under the Patent Cooperation Treaty (PCT) and a Continuation In Part (CIP) will be filed to broaden both the geographic and technological scope of the Intellectual Property protection and to add additional aspects to the technology that have been discovered or invented since the original application date.

Full details of the granted patent, with the complete list of twenty-five granted claims will be available upon Gazette publication.


Oct. 28, 2020

Narrative of Some Issues Faced By NanoLogix Since May Announcement of Rapid COVID19 test

Issues are Resolved and NanoLogix Is Proceeding with Technology Development and Awaiting the Allowed Patent Issuance

Appreciation to Congressman Tim Ryan for his Interest and Assistance in Resolution

NanoLogix is presenting this narrative to illustrate the unusual and unanticipated challenges that were presented to the Company beginning immediately after our announcement of the invention and the initial results for a rapid viral detection test technology applicable to COVID-19 and other viruses.

Within a few days of our May 3rd announcement covering this news, we were reported by an unknown party or parties to FINRA, the FDA, and the SEC.

During the course of these events, and until their resolution, we did not believe we could approach investors for funding necessary for the further development of the technology. Nor could we seek development partners until this "Matter" was resolved. NanoLogix was delayed and blocked for approximately five months until the resolution of the "Matter" with no action recommended.

For the full narrative, please follow this link:

https://nanologix.com/narrative-of-some-issues-faced-by-nanologix-since-may-announcement-of-rapid-covid19-test-and-since-resolved/


Oct. 14, 2020

NanoLogix Is Researching FDA EUA Requirements For COVID-19 Testing Related to Recently Allowed Patent

1st For Whole Virus Detection, 2nd For Antibody Detection

NanoLogix Welcomes David R. Barnhizer as Vice President For Strategic Analysis and Development

NanoLogix is researching FDA requirements for EUA's for two of the 25 covered claims in the recently allowed patent application focused upon Rapid Virus Detection. Now that there has been allowance for issue of the patent with all 25 claims allowed, NanoLogix can justify devoting resources to this process and specifics.

Upon successful results for work currently being performed by a third party to apply NanoLogix technology to a separate testing platform for COVID19 detection, other applications may follow. Once the patent is issued we will reveal the broad and detailed extent of allowed claims for this technology.

Within the next two weeks NanoLogix will be releasing a narrative detailing challenges that were presented to the Company from outside sources apparently opposed to either the technology development or the Company since our May release of the COVID19 news.

David Barnhizer is Professor of Law Emeritus at the Cleveland State University. He received law degrees from the Ohio State University where he graduated summa cum laude and from Harvard University where he was a Ford Foundation Urban Law Fellow, a CLEPR Clinical Teaching Fellow, and earned a Masters of Law degree. He was Articles Editor of the Ohio State Law Journal, and began his legal career as a Reginald Heber Smith Community Lawyer in Colorado with the Colorado Springs Legal Services Office.

He has been a Senior Research Fellow at the University of London's Institute for Advanced Legal Studies, a frequent Visiting Professor at the Westminster University School of Law in London, taught human rights and international environmental law in St. Petersburg, Russia in a joint program with St. Petersburg State University, and instructed in Harvard’s Intersession program in Trial Advocacy.

He has served as Senior Adviser in the International Program of the Natural Resources Defense Council (NRDC). He was a Senior Fellow with Earth Summit Watch, and a board member of the International Shrimp Action Network (ISANET) an international NGO network made up of more than twenty NGOs involved in environment, development and coastal zone management in developing countries. He was Executive Director of the Washington, DC-based Year 2000 Committee, and has consulted extensively with environmental and development organizations. These include the World Resources Institute, the International Institute for Environment and Development, the United Nations Development Program, the President’s Council on Environmental Quality, the World Bank, the United Nations Food and Agricultural Organization (FAO), the World Wildlife Fund, the Mongolian government, and the Center for Global Change.

In addition, he spent nine years as a member of the board of directors for Performance Capital Management, and was a strategic consultant for Sovonics Solar Systems, a subsidiary of British Petroleum. He also served as Rapporteur for the Foresight Capability Workshop of the Energy and Commerce Committee of the US House of Representatives and has worked on projects in conjunction with numerous federal agencies.

He has written over fifty law review articles and book chapters, and authored and edited a number of books, including The Warrior Lawyer, a work developing the strategic principles of Sun Tzu's Art of War and Musashi's A Book of Five Rings. Other books include Strategies for Sustainable Societies, Environment Cleveland, The Blues of a Revolution, two volumes on Effective Strategies for Protecting Human Rights, and Hypocrisy & Myth: The Hidden Order of the Rule of Law co-authored with Daniel Barnhizer.

The most recent book, co-authored with Michigan State University Professor of Law Daniel Barnhizer, is The Artificial Intelligence Contagion: Can Democracy Withstand the Imminent Transformation of Work, Wealth, and the Social Order? CONTAGION has been ranked as high as # 1 in Book Authority’s All-Time Top 100 books on Robotics and in the top ten in Book Authority’s All-Time list on artificial intelligence.


Oct. 8, 2020

NanoLogix Notified of Patent Allowance for Sub 1-Hour Covid-19 Detection Technology

Allowance for All 25 Patent Claims Issued September 8th, 3-1/2 months after May 18th Filing Date

Additional and related news to be released next week.


Oct. 5, 2020

NanoLogix Covid-19 Detection Test Update

Partial Funding received from NanoLogix Directors Options Exercise

NanoLogix has enlisted the services of a company with an advanced diagnostic platform that can deliver lab-quality results at point-of-care (POC). That company will perform an initial feasibility assessment of our COVID-19 viral assay on their rapid POC system. Partial funding for the first phase of the feasibility assessment is being provided through NanoLogix Director and Chief Medical Officer Dr. Jonathan Faro and Director Dr. Sebastian Faro exercise of options for 3 million shares. Those exercised shares are restricted from trading for a period of one year from issuance

The Directors' action reflects their belief in the NanoLogix rapid viral detection technology and its potential.

Independent laboratory work in Houston on a separate phase and aspect of the testing technology will begin after initial results from the above-mentioned work.


Aug. 7, 2020

NanoLogix Sub 1-Hour Covid-19 Detection Test Further Developments

NanoLogix Begins Collaborative Efforts With Diagnostic Company and an Independent Laboratory

NanoLogix announces it has begun working with two entities to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses. One is a West Coast diagnostic company and the other a long-established independent Houston laboratory.

The overall intent of this work is to obtain results to enable a detailed submission of those results to the US FDA for the purpose of receiving an Emergency Use Authorization, enabling use of the technology as a Point of Care (POC) rapid test. Secondary benefits should be publication of the resulting data in the form of at least two peer-reviewed science/medical journal papers. Grant applications are anticipated by at least one of the partners to the work. The projections for the timeline for the work range from one+ month for the independent laboratory to more than three months for the diagnostic company.

While we have achieved results in less than one hour with our own laboratory work, indications from one of the entities are that the test can potentially be streamlined to the point where results may be obtained in as little as twenty minutes in a form that makes the test more user and consumer friendly. This projected ease of use positions the assay for potential home use if and when it is approved by the FDA.

NanoLogix has entered into mutual confidentiality agreements with both involved groups. We faithfully respect those agreements as essential to the success of business and technology development. In the past, when we have released information mentioning arrangements with others, such as the US EPA, the University of Texas Health Science Center in Houston, Battelle Biomedical research Center, and individuals recently employed or otherwise associated with NanoLogix, those groups began receiving calls and contacts from persons identifying themselves as shareholders of NanoLogix. The calls ranged from in subject from simple curiousity to demands to reveal the nature of the technology development and business relationship with NanoLogix. The effects were potentially damaging to NanoLogix and its interests, to include investors. We will not release further information regarding the recent associations until all parties are prepared to do so.